[HTML][HTML] Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies
AW Schmid, B Fauvet, M Moniatte… - Molecular & Cellular …, 2013 - ASBMB
The development of novel therapies against neurodegenerative disorders requires the
ability to detect their early, presymptomatic manifestations in order to enable treatment
before irreversible cellular damage occurs. Precocious signs indicative of
neurodegeneration include characteristic changes in certain protein levels, which can be
used as diagnostic biomarkers when they can be detected in fluids such as blood plasma or
cerebrospinal fluid. In the case of synucleinopathies, cerebrospinal alpha-synuclein (α-syn) …
ability to detect their early, presymptomatic manifestations in order to enable treatment
before irreversible cellular damage occurs. Precocious signs indicative of
neurodegeneration include characteristic changes in certain protein levels, which can be
used as diagnostic biomarkers when they can be detected in fluids such as blood plasma or
cerebrospinal fluid. In the case of synucleinopathies, cerebrospinal alpha-synuclein (α-syn) …